27 August 2021 | News
The molecular test kits are expected to be available in a phased manner, starting from September 2021
Siemens Healthineers has announced local manufacturing of molecular testing kits, including COVID-19 testing (IMDX SARS-CoV2 Multiplex RTPCR) as well as other molecular testing kits at its state-of-the-art facility at Vadodara, Gujarat.
The facility was inaugurated jointly by Krishnan Seshan, Executive Director (Finance and Administration) of Siemens Healthcare and Arpan Malhotra, Head of Diagnostics, Siemens Healthineers, India.
"The kits are designed and developed by Siemens Healthineers along with researchers from Indian universities and research centers", said Arpan Malhotra.
The IMDX SARS-CoV2 Multiplex RTPCR kits will be produced in compliance with the guidelines prescribed by the Indian statutory bodies and conform to the highest global standards.
The existing manufacturing facility licensed as per Medical Device Rules, 2017 (MDR 2017), comprises of two product lines namely Urine Analysis strips and AUTOPAK Biochemistry Reagents.
As a part of the skill development initiative, the facility also serves as a Centre of Excellence for training in Laboratory Diagnostics, Point-of-Care Testing and Diagnostic Imaging, across the South Asia region.